Table 2.

Patient’s characteristics, treatment choices and outcomes (n = 313)

Characteristics (N = 313)	HCV (n = 154) n (%)	HCV/HIV (n = 124) n (%)	HCV/CKD (n = 35) n (%)	P value
Genotype
1a	39 (25.3)	63 (50.8)	11 (31.4)	< 0.001*
1b	29 (18.8)	13 (10.5)	08 (22.9)
2	03 (1.9)	02 (1.6)	–
3/3a	70 (45.5)	26 (21.0)	14 (40.0)
4/4d	12 (7.8)	19 (15.3)	02 (5.7)
5	01 (0.6)	01 (0.8)	–
Tx experience and liver status
Non-cirrhotic/naïve	45 (29.2)	73 (58.9)	17 (48.6)	< 0.001*
Non-cirrhotic/pre-treated	23 (14.9)	29 (23.4)	05 (14.3)
Cirrhotic/naïve	39 (25.3)	14 (11.3)	10 (28.6)
Cirrhotic/pre-treated	47 (30.5)	08 (6.5)	03 (8.6)
Tx choices
1st line	151 (98.1)	110 (88.7)	20 (57.1)	< 0.001*
2nd line	03 (1.9)	10 (8.1)	13 (37.1)
3rd line	–	02 (1.6)	–
Deferred/med change req.	–	02 (1.6)	02 (5.7)
Tx outcomes
Not commenced treatment	01 (0.6)	12 (9.7)	02 (5.7)
Stopped early, lost to FU	02 (1.3), 01 (0.6)	02 (1.6), 07 (5.6)	02 (5.7), 00
Completed treatment	150 (97.4)	103 (83.1)	31 (88.6)
SVR 12 achieved	129 (83.8)	84 (67.7)	26 (74.3)	< 0.001*
ETR achieved/awaiting SVR12	14 (9.1)	15 (12.1)	02 (5.7)
SVR 12 not achieved (failed/relapsed)	07 (4.5)	04 (3.2)	03 (8.6)
mITT % cure rate	95.3%	96.1%	90.3%

HCV hepatitis C virus, HIV human immunodeficiency virus, CKD chronic kidney disease, Tx treatment (1st line, 2nd line, 3rd line are in accordance with NHSE hepatitis C treatment run rate card at the time of treatment), SVR sustained virological response, FU follow up, modified ITT modified intention to treat analysis; representing; Tx of HCV patients was approved at MDT but not commenced and ongoing treatments awaiting 12 week SVR

*Pearson Chi square test shows a significant difference (P value 0.05 or less) of the variable among treated groups